Short-term effect of combined therapy with Jinlong Capsule and transcatheter arterial chemoembolization on patients with primary hepatic carcinoma and its influence on serum osteopontin expression.
OBJECTIVE
To observe the clinical combination effect of Jinlong Capsule (JLC) and transcatheter arterial chemoembolization (TACE) on the patients with primary hepatic carcinoma (PHC) and JLC' s influence on serum osteopontin (OPN) expression and elucidate the correlation between the serum OPN level and curative effect of JLC and TACE.


METHODS
A total of 98 patients with PHC were observed in a randomized controlled trial (RCT). They were assigned to the Chinese medicine (CM) group (53 patients who were treated with TACE and JLC) and the intervention group (45 patients who were treated with TACE only). The serum OPN levels were measured before and after treatment by quantitative sandwich enzyme-linked immunosorbent assay (ELISA). Forty healthy people were assigned to the control group. The clinical efficacy was observed and Karnofsky score (KPS) was graded.


RESULTS
The clinical efficacy of the CM group (60.38%) was better than that of the intervention group (40.00 %), and the KPS (84.35+/-12.19) was higher than the intervention group (69.86+/- 11.58) (P<0.05). The serum OPN levels before and after treatment in the patients with PHC were significantly elevated compared with those in the control group (P<0.01). After treatment, the OPN levels in CM group (117.69 <+/-78.50) were significantly lower compared with those in intervention group (151.09+/-83.90, P<0.05). The OPN levels of responders were remarkably lowered than the non-responders after treatment, and the level of OPN in the CM group was lower than the intervention group (P<0.05).


CONCLUSIONS
The short-term clinical efficacy and the quality of life of patients with PHC can be improved by combining JLC with TACE. The serum OPN levels in PHC patients can reflect the curative effect of treatment and the prognosis of the disease.
Wu
Guo-lin
GL
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou (310003), China. wuguolin28@yahoo.com.cn
Zhang
Li
L
Li
Tian-yi
TY
Chen
Jiu
J
Yu
Guo-you
GY
Li
Jian-ping
JP
D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D002214:Capsules; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000378:metabolism / Q000628:therapy*; D002406:Catheterization, Peripheral / Q000379:methods; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D003131:Combined Modality Therapy; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008099:Liver / Q000098:blood supply; D008113:Liver Neoplasms / Q000097:blood / Q000378:metabolism / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D053495:Osteopontin / Q000032:analysis / Q000097:blood* / Q000378:metabolism; D013997:Time Factors; D016896:Treatment Outcome
D000972:Antineoplastic Agents, Phytogenic; D002214:Capsules; D004365:Drugs, Chinese Herbal; C552037:jinlong; D053495:Osteopontin
Nat Med. 2003 Apr;9(4):416-23
12640447
Cancer Res. 1985 Nov;45(11 Pt 2):5818-23
4053052
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):184-90
14734468
Ann Surg. 2002 Apr;235(4):466-86
11923602
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
Pathol Int. 2002 Jan;52(1):19-24
11940202